Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations
August 11, 2022 07:00 ET
|
Passage Bio
PHILADELPHIA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference
August 05, 2022 07:00 ET
|
Passage Bio
PHILADELPHIA, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Reports Second Quarter 2022 Financial Results and Provides Recent Business Highlights
August 04, 2022 07:00 ET
|
Passage Bio
Advanced Imagine-1 clinical trial for GM1 gangliosidosis to recruitment of final cohort, Cohort 4, in dose-ascending phase of study following recommendation by Independent Data Monitoring Committee...
Passage Bio to Report Second Quarter 2022 Financial Results on August 4, 2022
July 28, 2022 07:30 ET
|
Passage Bio
PHILADELPHIA, July 28, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 21, 2022 16:01 ET
|
Passage Bio
PHILADELPHIA, July 21, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Appoints Michael Kamarck, Ph.D. to Board of Directors
July 06, 2022 07:00 ET
|
Passage Bio
PHILADELPHIA, July 06, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
June 09, 2022 07:30 ET
|
Passage Bio
PHILADELPHIA, June 09, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Receives FDA Clearance of IND Application for PBML04 for Treatment of Metachromatic Leukodystrophy
June 08, 2022 07:30 ET
|
Passage Bio
• PBML04 represents the company’s fourth program to receive IND clearance PHILADELPHIA, June 08, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines...
Passage Bio Announces Leadership Transition
June 01, 2022 07:30 ET
|
Passage Bio
Bruce Goldsmith, Ph.D. to step down as president and chief executive officer and member of board of directors, will serve as a strategic advisor for a transition periodEdgar B. (Chip) Cale, current...
Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
May 20, 2022 16:01 ET
|
Passage Bio
PHILADELPHIA, May 20, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...